Inhaled Corticosteroids Versus Observation for Patients With Decreased Lung Function Status

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00656916

Recruitment Status : Terminated (Terminated due to slow accrual.)

First Posted : April 11, 2008

Results First Posted : April 23, 2012

Last Update Posted : April 23, 2012

Sponsor:

Information provided by (Responsible Party):

M.D. Anderson Cancer Center

Study Description

Brief Summary:

The goal of this clinical research study is to compare lung function of patients who inhale steroids in the early stages of post-transplant constrictive bronchiolitis (PTCB) to patients who continue with standard of care.

Condition or disease	Intervention/treatment	Phase
Bronchiolitis	Drug: Fluticasone Propionate	Phase 2

Show detailed description

Detailed Description:

The Study Drug:

Fluticasone propionate is designed to stop the inflammatory action of asthma cells in PTCB.

Screening Tests:

Before you can start treatment on this study, you will have a pulmonary function test (PFT). For this tests, you will be asked to breathe in several different ways while you have a mouthpiece in your mouth to test your lung function.

Study Groups:

If you are found eligible to take part in this study, participants will be assigned to receive fluticasone propionate.

Study Drug Administration:

You will receive fluticasone propionate twice a day by oral inhalation. The study drug will be taken through a metered-dose inhaler. You will be given detailed instructions by the research nurse or clinic nurse at your first study visit.

You will use an Albuterol MDI (rescue inhaler) when needed for shortness of breath. This inhaler is commonly used to treat asthma, chronic obstructive pulmonary disease (COPD), and other respiratory problems. Your clinic nurse will tell you how to use it.

You will fill out a diary to record how often you use the rescue inhaler. You will also record when you take the study drug each week. The diary will be collected at each visit. The diary will take a few minutes to fill out.

Study Visits:

On Day 1, the following tests and procedures will be performed:

You will have a 6-minute walk test. To perform the 6-minute walk test, you will walk as far as possible around cones on a flat indoor course that is about 40 yards long. You will walk at your own pace and can take breaks at any time. After 6 minutes, the study staff will check the total distance you have walked. Your vital signs (blood pressure, heart rate, temperature, and breathing rate) will be measured before and after the walk. Your oxygen saturation levels will be checked throughout the test. To measure oxygen saturation, you will wear a small clip on your finger that will send the oxygen saturation data to a small computer.
You will also complete St. George's respiratory questionnaire.The questionnaire will have 17 multiple choice or true/false questions about your lung function and overall health. A research nurse will be available to help you with the questionnaire. It will take about 30 minutes to complete.
You will also complete a NIOX flex test. This measures the amount of nitric oxide in your lungs. While seated, you will exhale and then place the NIOX filter in your mouth. You will then inhale to full lung capacity over 2-3 seconds. Then you will exhale slowly keeping constant flow with the aid of a meter on the computer screen. This is repeated until 3 valid readings are measured and then the test is completed.

Between Weeks 4 and 6, you will have a PFT.

At 3 months, 6 months, and 1 year, the following tests and procedures will be performed:

You will have a PFT.
You will complete the St. George's respiratory questionnaire.
You will have a 6-minute walk test.
You will have an exhaled nitric oxide (NIOX) Flex test, only at baseline, 3 and 6 months.

Length of Study:

You will be taken off study if the disease gets worse or if intolerable side effects occur. All patients whose condition stayed the same or improved at the end of 1 year will continue study drug and visit schedule.

End-of-Study Visit:

Before you are considered off-study, you will have an end-of-study visit. The following tests and procedures will be performed:

You will have a PFT.
You will complete the St. George's respiratory questionnaire.
You will have a 6-minute walk test.

Follow-Up:

Patients may be contacted by mail or by phone to answer follow-up questions. Follow-up questions and contact frequency will be based on your condition. If you are contacted by phone, the conversation will last about 15 minutes.

This is an investigational study. Fluticasone propionate is FDA approved and commercially available for use in asthma and COPD patients. It's use in PTCB is investigational. Up to 40 patients will take part in this study. All will be enrolled at M. D. Anderson.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	1 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Randomized Study of Early Treatment With Inhaled Corticosteroids Versus Observation for Patients Who Have Decreased Lung Function Status Post Allogeneic Stem Cell Transplantation
Study Start Date :	March 2008
Actual Primary Completion Date :	December 2010
Actual Study Completion Date :	December 2010

Resource links provided by the National Library of Medicine

Drug Information available for: Fluticasone propionate Fluticasone Fluticasone furoate

Genetic and Rare Diseases Information Center resources: Bronchiolitis Obliterans Organizing Pneumonia

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Fluticasone Propionate 440 micrograms twice daily by oral inhalation.	Drug: Fluticasone Propionate 440 micrograms twice daily by oral inhalation.
No Intervention: Observational Group Comparator group, no intervention.

Outcome Measures

Primary Outcome Measures :

Lung Function Non-deterioration Rate [ Time Frame: Baseline and three months ]
Lung function non deterioration rate defined by change of forced expiratory volume in one second (FEV1) of < 20%. FEV1, maximal amount of air forcefully exhaled in 1 second, converted to percentage of normal, calculated from a pulmonary function test (PFT) performed at baseline and three months.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients >/=18 years of age.
Patients must be engrafted and at least 80 days post allogeneic hematopoietic stem cell transplantation.
New onset airflow obstruction defined as decline of forced expiratory volume in 1 second (FEV1) percent predicted >/= 15%.
Total Lung Capacity (TLC) > 85% to rule out restrictive lung disease.
Patient must be willing to comply with all study procedures and capable of signing informed consent.

Exclusion Criteria:

Patients with active pulmonary infection.
Patients with known hypersensitivity to corticosteroids

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00656916

Locations

Layout table for location information

United States, Texas
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Investigators

Layout table for investigator information

Principal Investigator:	Lara Bashoura, MD	M.D. Anderson Cancer Center

More Information

Additional Information:

MD Anderson Cancer Center This link exits the ClinicalTrials.gov site

Layout table for additonal information

Responsible Party:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00656916
Other Study ID Numbers:	2007-0390
First Posted:	April 11, 2008 Key Record Dates
Results First Posted:	April 23, 2012
Last Update Posted:	April 23, 2012
Last Verified:	March 2012

Keywords provided by M.D. Anderson Cancer Center:


Post-Transplant Constrictive Bronchiolitis Bronchiolitis Fluticasone Propionate	Inhaled Corticosteroids Lung Condition PTCB

Additional relevant MeSH terms:

Layout table for MeSH terms

Bronchiolitis Respiratory Tract Diseases Bronchitis Respiratory Tract Infections Infections Bronchial Diseases Lung Diseases, Obstructive Lung Diseases Fluticasone Xhance	Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Dermatologic Agents Anti-Allergic Agents

To Top